Search Results for “EC” – Page 562 – media

TESARO Announces Collaboration to Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the combination of the PD-L1 antibody atezolizumab (TECENTRIQ®) and TESARO’s PARP-inhibitor ZEJULA® (niraparib) in patients with metastatic bladder cancer.
- Source: ir.tesarobio
- 758
- March 6, 2018
antibody bladder cancer Market Views oncology
Finch Therapeutics Raises $36 Million Series B, Bringing Total to $77 Million

Finch Therapeutics, headquartered in Somerville, Massachusetts, closed on an oversubscribed Series B financing worth $36 million. Since the company’s launch, it has raised $77 million. Series B investors included Shumway Capital, Willett Advisors, Morgan Noble and Avenir Growth Capital.
- Source: Biospace
- 562
- March 6, 2018
Market Views microbiome Series
The right amount of vitamin D can reduce mortality risk says new study

A new Norwegian study suggests that getting the right amount of vitamin D could substantially reduce an individual's risk of death.
- Source: msn
- 633
- March 6, 2018
cardiovascular diseases Researches vitamin D
Sanofi files Dupixent for severe asthma

US regulators have accepted for review Sanofi/Regeneron’s biologic Dupixent as an add-on maintenance treatment in certain adults and adolescents with moderate-to-severe asthma.
- Source: pharmatimes
- 944
- March 6, 2018
asthma Dupixent New Approvals Sanofi
Major Medical Associations Feud Over Diabetes Guidelines

A major medical association today suggested that doctors who treat people with Type 2 diabetes can set less aggressive blood sugar targets. But medical groups that specialize in diabetes sharply disagree.
- Source: NPR
- 514
- March 6, 2018
diabetes Researches type 2 diabetes
Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups

After a string of announcements a few years back, there’s been few new, high-profile biotech startups taking shape in New York. But that quiet period might be coming to an end this morning with the arrival of Quentis Therapeutics, a cancer immunotherapy startup born from the lab of former Weill Cornell Medicine dean and immunologist Laurie Glimcher. The company makes its debut today with a $48 million Series A round.
- Source: Xconomy
- 539
- March 5, 2018
cancer immunotherapy Series
Cardiovascular Systems, Inc. and OrbusNeich Announce FDA Clearance of the First and Only 1.0mm Coronary Balloon in the U.S.

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the OrbusNeich® 1.0mm Sapphire® II PRO coronary balloon.
- Source: Enhancedonlinenews
- 490
- March 5, 2018
artery disease New Approvals Sapphire
Ancon Medical Launches Human Trials in Search for Flu Biomarker

With its worldwide impact and mounting death toll, the 2017-2018 influenza season shows that the viral disease isn’t just a fever and the sniffles, but rather a dangerous disease that can spread rapidly between people. That’s why a leading healthcare technology company is pushing forward with trials that can help doctors and medical staff easily identify the disease early in the process through a simple breath test.
- Source: Cision
- 921
- March 5, 2018
flu influenza Researches
Philips to launch new version of HealthSuite with AI and analytics at HIMSS18

At HIMSS18, Philips plans to announce several new additions to its line of connected care products. A new management system called FocusPoint will help give hospitals more visibility into the performance of their patient monitoring technology.
- Source: MobiHealthNews
- 492
- March 5, 2018
AI Company Insight digital health
MeiraGTx Earns EMA PRIME Designation for Achromatopsia Gene Therapy Candidate

A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe. Gene therapy company MeiraGTx said the European Medicines Agency granted Priority Medicines (PRIME) designation to its candidate A002 for treatment of achromatopsia.
- Source: biospace
- 411
- March 5, 2018
achromatopsia eye disorder New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.